PortfoliosLab logoPortfoliosLab logo
CNC vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CNC vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Centene Corporation (CNC) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CNC achieves a 58.03% return, which is significantly higher than AZN's 0.81% return. Over the past 10 years, CNC has underperformed AZN with an annualized return of 6.71%, while AZN has yielded a comparatively higher 15.85% annualized return.


CNC

1D
4.33%
1M
16.21%
YTD
58.03%
6M
71.67%
1Y
17.89%
3Y*
-1.96%
5Y*
-1.92%
10Y*
6.71%

AZN

1D
-2.37%
1M
-0.71%
YTD
0.81%
6M
1.53%
1Y
28.04%
3Y*
9.54%
5Y*
12.08%
10Y*
15.85%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CNC vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CNC
Centene Corporation
58.03%-32.07%-18.37%-9.51%-0.47%37.26%-4.52%9.05%14.29%78.52%
AZN
AstraZeneca PLC
0.81%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between CNC and AZN is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.11

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (10Y)
Calculated over the trailing 10-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Dec 14, 2001

0.23

The correlation between CNC and AZN shifts across timeframes, from 0.09 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

CNC:

$32.23B

AZN:

$283.40B

EPS

CNC:

-$13.07

AZN:

$6.66

PS Ratio

CNC:

0.16

AZN:

4.69

PB Ratio

CNC:

1.50

AZN:

5.99

Total Revenue (TTM)

CNC:

$198.10B

AZN:

$60.44B

Gross Profit (TTM)

CNC:

$29.57B

AZN:

$49.37B

EBITDA (TTM)

CNC:

-$5.11B

AZN:

$20.47B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CNC vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNC
CNC Risk / Return Rank: 5252
Overall Rank
CNC Sharpe Ratio Rank: 5252
Sharpe Ratio Rank
CNC Sortino Ratio Rank: 5050
Sortino Ratio Rank
CNC Omega Ratio Rank: 5959
Omega Ratio Rank
CNC Calmar Ratio Rank: 5050
Calmar Ratio Rank
CNC Martin Ratio Rank: 4949
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 7373
Overall Rank
AZN Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7373
Sortino Ratio Rank
AZN Omega Ratio Rank: 6969
Omega Ratio Rank
AZN Calmar Ratio Rank: 7474
Calmar Ratio Rank
AZN Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNC vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Centene Corporation (CNC) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CNCAZNDifference
Sharpe ratioReturn per unit of total volatility

-0.83

Sortino ratioReturn per unit of downside risk

-1.06

Omega ratioGain probability vs. loss probability

1.15

1.21

-0.06

Calmar ratioReturn relative to maximum drawdown

0.32

1.83

-1.51

Martin ratioReturn relative to average drawdown

0.53

4.90

-4.37

CNC vs. AZN - Sharpe Ratio Comparison

The current CNC Sharpe Ratio is 0.28, which is lower than the AZN Sharpe Ratio of 1.11. The chart below compares the historical Sharpe Ratios of CNC and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CNCAZNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.28

1.11

-0.83

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.05

0.51

-0.56

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.17

0.64

-0.46

Sharpe Ratio (All Time)

Calculated using the full available price history

0.40

0.49

-0.09

Drawdowns

CNC vs. AZN - Drawdown Comparison

The maximum CNC drawdown since its inception was -74.07%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for CNC and AZN.


Loading charts...

Drawdown Indicators


CNCAZNDifference

Max Drawdown

Largest peak-to-trough decline

-74.07%

-48.94%

-25.13%

Max Drawdown (1Y)

Largest decline over 1 year

-55.50%

-15.43%

-40.07%

Max Drawdown (3Y)

Largest decline over 3 years

-68.65%

-27.87%

-40.78%

Max Drawdown (5Y)

Largest decline over 5 years

-74.07%

-27.87%

-46.20%

Max Drawdown (10Y)

Largest decline over 10 years

-74.07%

-27.87%

-46.20%

Current Drawdown

Current decline from peak

-33.11%

-12.90%

-20.21%

Average Drawdown

Average peak-to-trough decline

-22.15%

-11.37%

-10.78%

Ulcer Index

Depth and duration of drawdowns from previous peaks

33.84%

5.75%

+28.09%

Volatility

CNC vs. AZN - Volatility Comparison

Centene Corporation (CNC) has a higher volatility of 11.25% compared to AstraZeneca PLC (AZN) at 7.42%. This indicates that CNC's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CNCAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.25%

7.42%

+3.83%

Volatility (6M)

Calculated over the trailing 6-month period

36.53%

17.47%

+19.06%

Volatility (1Y)

Calculated over the trailing 1-year period

64.57%

25.55%

+39.02%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

39.51%

24.02%

+15.49%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

38.53%

24.94%

+13.59%

Dividends

CNC vs. AZN - Dividend Comparison

CNC has not paid dividends to shareholders, while AZN's dividend yield for the trailing twelve months is around 2.93%.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
2.93%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
CNC
Centene Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

CNC vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Centene Corporation and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B20.00B30.00B40.00B50.00B20222023202420252026
49.94B
15.29B
(CNC) Total Revenue
(AZN) Total Revenue
Values in USD except per share items

CNC vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Centene Corporation and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
21.9%
82.5%
Portfolio components
CNC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Centene Corporation reported a gross profit of 10.94B and revenue of 49.94B. Therefore, the gross margin over that period was 21.9%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

CNC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Centene Corporation reported an operating income of 1.86B and revenue of 49.94B, resulting in an operating margin of 3.7%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

CNC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Centene Corporation reported a net income of 1.54B and revenue of 49.94B, resulting in a net margin of 3.1%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.


Frequently Asked Questions


CNC and AZN have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CNC has higher volatility (11.25%) compared to AZN (7.42%). In terms of maximum drawdown, CNC dropped -74.07% vs AZN's -48.94%.

AZN currently has the higher Sharpe Ratio (1.11 vs 0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CNC and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer